S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Forecast, Price & News

$10.67
+0.52 (+5.12%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.83
$10.73
50-Day Range
$5.73
$10.67
52-Week Range
$5.41
$22.98
Volume
212,725 shs
Average Volume
258,327 shs
Market Capitalization
$529.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.67

Edgewise Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
112.4% Upside
$22.67 Price Target
Short Interest
Bearish
12.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Edgewise Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$994,980 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.49) to ($1.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

1066th out of 1,283 stocks

Pharmaceutical Preparations Industry

508th out of 615 stocks

Edgewise Therapeutics logo

About Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics Stock Up 5.1 %

Edgewise Therapeutics stock opened at $10.67 on Friday. The stock has a 50-day simple moving average of $8.30 and a 200 day simple moving average of $9.48. The stock has a market capitalization of $529.02 million, a price-to-earnings ratio of -9.36 and a beta of -0.19. Edgewise Therapeutics has a 12-month low of $5.41 and a 12-month high of $22.98.

Edgewise Therapeutics (NASDAQ:EWTX - Get Rating) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). As a group, sell-side analysts anticipate that Edgewise Therapeutics will post -1.49 EPS for the current year.

Analyst Ratings Changes

EWTX has been the topic of several analyst reports. SVB Leerink reaffirmed an "outperform" rating on shares of Edgewise Therapeutics in a report on Monday, April 25th. Royal Bank of Canada began coverage on shares of Edgewise Therapeutics in a report on Wednesday, April 13th. They set an "outperform" rating and a $31.00 price objective for the company. Finally, The Goldman Sachs Group reduced their target price on Edgewise Therapeutics from $8.00 to $5.00 and set a "neutral" rating on the stock in a report on Tuesday, May 24th.

Insider Buying and Selling

In other Edgewise Therapeutics news, General Counsel John R. Moore sold 10,800 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of $7.42, for a total value of $80,136.00. Following the transaction, the general counsel now directly owns 3,000 shares in the company, valued at approximately $22,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Edgewise Therapeutics news, Director Orbimed Advisors Llc purchased 138,000 shares of the stock in a transaction dated Wednesday, May 18th. The stock was bought at an average price of $7.21 per share, for a total transaction of $994,980.00. Following the transaction, the director now directly owns 13,497,456 shares in the company, valued at $97,316,657.76. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel John R. Moore sold 10,800 shares of the business's stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $7.42, for a total transaction of $80,136.00. Following the sale, the general counsel now directly owns 3,000 shares of the company's stock, valued at $22,260. The disclosure for this sale can be found here. Insiders sold 125,529 shares of company stock worth $884,360 in the last quarter.

Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EWTX Stock News Headlines

Analyst Ratings for Edgewise Therapeutics
Edgewise Therapeutics GAAP EPS of -$0.26 beats by $0.02
Why Edgewise Therapeutics Is Rising In Pre-market?
Edgewise Therapeutics Rings the Opening Bell
Notable Edgewise Therapeutics Insider Makes $105K Sale
See More Headlines

Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EWTX Company Calendar

Last Earnings
5/11/2022
Today
8/07/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EWTX
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.67
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+112.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-42,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.57 per share

Miscellaneous

Free Float
N/A
Market Cap
$529.02 million
Optionable
Not Optionable
Beta
-0.19

Key Executives

  • Dr. Kevin Koch Ph.D. (Age 62)
    Pres, CEO & Director
    Comp: $845.33k
  • Dr. Badreddin Edris Ph.D. (Age 35)
    Co-Founder & Independent Director
    Comp: $36.26k
  • Dr. Behrad Derakhshan Ph.D. (Age 42)
    Chief Bus. Officer
    Comp: $575.53k
  • Dr. Joanne M. Donovan M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $556.23k
  • Dr. Alan J. Russell Ph.D. (Age 52)
    Co-Founder, Chief Scientific Officer & Director
  • Mr. R. Michael Carruthers (Age 64)
    Chief Financial Officer
  • Mr. John R. Moore (Age 58)
    Gen. Counsel













EWTX Stock - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Edgewise Therapeutics stock.
View analyst ratings for Edgewise Therapeutics
or view top-rated stocks.

What is Edgewise Therapeutics' stock price forecast for 2022?

4 brokerages have issued 12 month price objectives for Edgewise Therapeutics' stock. Their EWTX stock forecasts range from $5.00 to $32.00. On average, they anticipate Edgewise Therapeutics' share price to reach $22.67 in the next year. This suggests a possible upside of 112.4% from the stock's current price.
View analysts' price targets for Edgewise Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Edgewise Therapeutics' stock price performed in 2022?

Edgewise Therapeutics' stock was trading at $15.28 at the beginning of the year. Since then, EWTX shares have decreased by 30.2% and is now trading at $10.67.
View the best growth stocks for 2022 here
.

When is Edgewise Therapeutics' next earnings date?

Edgewise Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our earnings forecast for Edgewise Therapeutics
.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.01.

When did Edgewise Therapeutics IPO?

(EWTX) raised $150 million in an IPO on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO.

What is Edgewise Therapeutics' stock symbol?

Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX."

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Board of Administration of Florida Retirement System (0.04%), Mirae Asset Global Investments Co. Ltd. (0.02%) and SG Americas Securities LLC (0.02%). Company insiders that own Edgewise Therapeutics stock include Alan J Russell, James E Flynn, John R Moore, Jonathan D Root and Orbimed Advisors Llc.
View institutional ownership trends for Edgewise Therapeutics
.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edgewise Therapeutics' stock price today?

One share of EWTX stock can currently be purchased for approximately $10.67.

How much money does Edgewise Therapeutics make?

Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $529.02 million. The company earns $-42,810,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Edgewise Therapeutics have?

Edgewise Therapeutics employs 31 workers across the globe.

How can I contact Edgewise Therapeutics?

Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for Edgewise Therapeutics is www.edgewisetx.com. The company can be reached via phone at 303-735-8373 or via email at ir@edgewisetx.com.

This page (NASDAQ:EWTX) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.